{"DataElement":{"publicId":"3025058","version":"1","preferredName":"Specimen Tumor Percentage Value","preferredDefinition":"Numeric value to represent the percentage of malignant cells in a sample or specimen as compared to adjacent normal tissue.","longName":"SPEC_TUM_PCT_VAL","context":"SPOREs","contextVersion":"2.31","DataElementConcept":{"publicId":"2013012","version":"3","preferredName":"Percent Tumor","preferredDefinition":"Percentage of abnormal or malignant cells in a sample or specimen as compared to adjacent normal tissue.","longName":"PCT_TUMOR","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2404687","version":"1","preferredName":"Neoplasm","preferredDefinition":"(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.","longName":"C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0094ACAF-11BC-1BCA-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-09-12","modifiedBy":"ONEDATA","dateModified":"2005-09-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2453117","version":"1","preferredName":"Percentage","preferredDefinition":"Percentage; a fraction or ratio with 100 understood as the denominator.","longName":"C25613","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D51E8D8-6DE7-387C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-27","endDate":null,"createdBy":"MAESKEB","dateCreated":"2006-02-27","modifiedBy":"ONEDATA","dateModified":"2006-02-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A78D1A47-081B-2951-E034-0003BA0B1A09","latestVersionIndicator":"Yes","beginDate":"2002-08-06","endDate":null,"createdBy":"JASUR","dateCreated":"2002-08-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2611609","version":"1","preferredName":"Specimen Tumor Percentage Value","preferredDefinition":"Numeric value to identify the percentage of overall tumor in a specimen.","longName":"SPEC_TUM_PCT_VAL","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","unitOfMeasure":"%","minLength":null,"maxLength":"3","minValue":null,"maxValue":null,"decimalPlace":"0","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008547","version":"1","preferredName":"Specimen Characteristics","preferredDefinition":"attributes of a patient's laboratory sample, including the source, condition, and fixative.","longName":"SPEC_CHAR","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22908C4-638F-4A74-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2611608","version":"1","preferredName":"Specimen Neoplasm Percentage Value","preferredDefinition":"Specimen; a bit of tissue or blood or urine that is taken or used for research purposes.:(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.:Percentage; a fraction or ratio with 100 understood as the denominator.:A numerical quantity measured or assigned or computed.","longName":"C19157:C3262:C25613:C25712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Specimen","conceptCode":"C19157","definition":"A part of a thing, or of several things, taken to demonstrate or to determine the character of the whole, e.g. a substance, or portion of material obtained for use in testing, examination, or study; particularly, a preparation of tissue or bodily fluid taken for examination or diagnosis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B6D59EA-A91E-4B34-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-03-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-03-11","modifiedBy":"ONEDATA","dateModified":"2007-03-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2B6D59EA-A92F-4B34-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-03-11","endDate":null,"createdBy":"REEVESD","dateCreated":"2007-03-11","modifiedBy":"REEVESD","dateModified":"2010-03-15","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811689","version":"1","longName":"SPOREs","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]},{"publicId":"2756809","version":"1","longName":"TCGA (The Cancer Genome Atlas)","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6044924","version":"1","longName":"Inactive CDEs as of March 2017","context":"NCIP"}]},{"publicId":"2961451","version":"1","longName":"Children's Oncology Group (COG)","context":"COG","ClassificationSchemeItems":[{"publicId":"2961452","version":"1","longName":"Statistics and Data Center","context":"COG"}]},{"publicId":"2976812","version":"1","longName":"GO Trial","context":"SPOREs","ClassificationSchemeItems":[{"publicId":"2989932","version":"1","longName":"GO New CDEs","context":"SPOREs"},{"publicId":"2976834","version":"1","longName":"GO Trial","context":"SPOREs"}]}],"AlternateNames":[{"name":"caBIG","type":"USED_BY","context":"NCIP"},{"name":"COG","type":"USED_BY","context":"COG"}],"ReferenceDocuments":[{"name":"Percentage of tumor tissue","type":"Preferred Question Text","description":"Percentage of tumor tissue","url":null,"context":"SPOREs"},{"name":"TCGA Question Text","type":"Alternate Question Text","description":"Percent Tumor","url":null,"context":"NCIP"},{"name":"COG CRF Text 1","type":"Alternate Question Text","description":"Percent tumor in sample tested:","url":null,"context":"COG"},{"name":"COG CRF Text 2","type":"Alternate Question Text","description":"Tumor content of sample (%):","url":null,"context":"COG"},{"name":"COG CRF TEXT 3","type":"Alternate Question Text","description":"Percentage of tumor in tested sample (%):","url":null,"context":"COG"},{"name":"COG CRF Text 4","type":"Alternate Question Text","description":"Institutional bone marrow aspirate tumor percentage:","url":null,"context":"COG"},{"name":"COG CRF Text 5","type":"Alternate Question Text","description":"Percentage of tumor in tested sample from central review:","url":null,"context":"COG"},{"name":"COG CRF Text 01","type":"Alternate Question Text","description":"Percent of tumor in bone marrow aspirate:","url":null,"context":"COG"},{"name":"COG CRF Text 6","type":"Alternate Question Text","description":"Percentage of tumor in tested sample:","url":null,"context":"COG"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"81DB8D09-E766-111C-E040-BB89AD430402","latestVersionIndicator":"Yes","beginDate":"2010-03-15","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-03-15","modifiedBy":"GDEEN","dateModified":"2023-01-26","changeDescription":"Curated to support GO Lung cancer trial at U Colorado.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}